ておき、HisTrap™ Kit で得た溶出液を 1 ml 流し、その後 500 μl ずつ PBS を流し溶出液を分取した。次に BCA™ Protein Assay Kit （PIERCE Biotechnology Inc., USA）を用い、buffer 置換した scFv 蛋白質の濃度を求め、残りの溶液を-80 ℃で保存した。

CBB 染色による scFv の発現確認

上記の操作により得た、PBS に溶解した scFv 蛋白質を 50 μg/ml にて調整した。その溶液 20 μl に 4×SDS を 6.7 μl を加え、95 ℃で 5 分間加熱しサンプルとした。サンプルは 20 μl （蛋白質量として 5 μg） アプライした。一方分子量マーカーとして Broad Range （BIO-RAD Laboratories, Inc., USA）を用いた。 15% polyacrylamide gel を用いて 20 mA で電気泳動 （SDS-PAGE） を行い、coomassie brilliant blue （CBB, Bio-Rad laboratories, Inc., USA)で 1 時間染色し milliQ で洗浄した後、30 kDa 付近に存在する scFv 蛋白質を確認した。尚、本蛋白質を研究代表者磯田が実施した CL-1 結合解析に供した。

C. 研究結果

研究結果は D 項に併せて記載。

D. 考察

D-1. C-CPEm19 の HCV 感染阻害活性

昨年度の検討で、C-CPE 構造変異体ライブラリの中から、CL1 に対して結合性を示す、C-CPE 変異体 C-CPEm19 を取得している。そこでまず、HCVpv の Huh7 細胞に対する感染を指標に、本分子の HCV 感染阻害活性を解析した。文献的に感染阻害効果が報告されている抗 CD81 抗体処理では、negative control の VSVpv の感染は全く阻害されていないのに対して、HCVpv の感染は濃度依存的に顕著な感染阻害が観察された（Fig. 1A）。一方、C-CPEm19 処理では 10 μg/ml 処理で弱冠の感染阻害効果が認められていたものの、濃度依存性は認められなかった（Fig. 1B）。

　CL1 抗体は、HCV 感染阻害分子として期待され

ているが、抗原性が低い上に CL1 蛋白質精製系が確立されておらず、CL1 抗体の作製は著しく立ち遅れている。そこで、CL 欠損マウスおよび BV を用いた膜蛋白質発現系を用いて、CL1 抗体作製系の構築を試みた。

C-2. CL-BV の免疫

CL-BV の免疫条件を種々検討したところ、CL 欠損マウスに CL-BV を免疫することで、血清中の抗 CL 抗体の抗体価が上昇することを見出した（Fig. 2）。CL 欠損マウスに CL-BV 1mg をアジュバント pertussis toxin B と共に皮下投与することで免疫した。免疫マウスの血清を用いた western blot により、CL-1 抗体の産生を確認した（Fig. 2）。当該マウスから脾臓を回収し、分担者角田の scFv ライブラリ作製に供した。

C-3. CL binder のスクリーニング

分担者角田が作製した scFv ライブラリを CL-1-BV 固相化したイムノチューブによってパンニングしたところ、3 回のスクリーニングによって若干の ratio の上昇が認められた（Fig. 3）。そこで、ファージクローンをモノクローン化し、CL-1 結合性を解析したところ、CL-1 結合性ファージクローンが複数認められた（Fig. 4）。そこで次に、CL-1-BV および CL-3-BV を用いた 2nd スクリーニングを行い、CL-1 特異的に結合性を示す、ファージクローンを 4 つ同定した（Fig. 5）。シークエンス解析したところ、このうち 3 は同じアミノ酸配列を有していた（Table 1）。

C-4. scFv 蛋白質の精製

そこで、CL1 結合性 scFv のリコンビナント蛋白質を作製するために、scFv 遺伝子断片を pET-16b に挿入し、ヒスタグ融合 scFv 蛋白質発現ベクターを構築し、大腸菌発現条件、精製条件を設定し、CL-1binder 候補分子、scFv47、scFv53 の作製に成功した。尚、これらの蛋白質は、代表者磯田が実施する CL1 結合性解析に供した。

E. 結論

昨年度、C-CPE 構造変異体ライブラリを用いたスクリーニングより、CL1 binder、C-CPEm19 が創製されていた。そこでまず、C-CPEm19 の HCV 感染阻害活性を解析したころ、感染阻害傾向が認められたもののその活性は弱いものであった。

2007 年の Nature に明記されているように、CL1 は抗原性が低い上に蛋白質精製法が確立されておらず、細胞外領域に対する抗体の作製は立ち遅れている。そこで、CL 欠損マウスおよび膜蛋白質発現系として注目されている BV システムを用いた CL1 抗体創製に向けたパイロットスタデイに着手した。種々免疫条件を変えることで、CL 発現 BV を CL 欠損マウスに免疫することで、CL に対する抗体価が上昇すること、本免疫マウスの脾臓を用いて作製した scFv ライブラリ中に CL1 binder が存在していることを見出した（詳細は、代表者磯田、分担者角田の報告内容を参照）。

今後は、本 scFv ライブラリ創製法をシステムアップすることで、druggable CL1 binder の創製を進めていく予定である。

G-1 論文発表

Suzuki H, Kakutani H, **Kondoh M,** Yagi K (2010) The safety of a mucosal vaccine using the C-terminal fragment of Clostridium perfringens enterotoxin. *Pharmazie*, **65**, 766-769.

Itoh A, Isoda K, **Kondoh M,** Kawase M, Watari A, Kobayashi M, Tamesada M, Yagi K (2010) Hepatoprotective Effect of Syringic Acid and Vanillic Acid on CCl₄-Induced Liver Injury. *Biol Pharm Bull*, **33**, 983-987.

Saeki R, **Kondoh M,** Kakutani H, Matsuhisa K, Takahashi A, Kakamu Y, Watari A, Yagi K (2010) A claudin-targeting molecule as a inhibitor of tumor metastasis. *J Pharmacol Exp Ther*, **334**, 576-582.

Kakutani H, **Kondoh M**, Fukasaka M, Suzuki H, Hamakubo T, Yagi K (2010) Mucosal Vaccination using claudin-4-targeting. *Biomaterials*, **31**, 5463-5471.

Yagi K, Kawase M, Isoda K, **Kondoh M** (2010) Development of novel culture system for regulation of hepatocyte function. *YAKUGAKU ZASSHI*, **130**, 537-543.

Kakutani H, **Kondoh M**, Saeki R, Fujii M, Watanabe Y, Mizuguchi H, Yagi K (2010) Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringents enterotoxin. *Eur J Pharm Biopharm*, **75**, 213-217.

Uchida H, **Kondoh M**, Hanada T, Takahashi A, Hamakubo T, Yagi K (2010) A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide. *Biochem Pharmacol*, **79**, 1437-1444.

Ushitora M, Sakurai F, Yamaguchi T, Nakamura S, **Kondoh M,** Yagi K, Kawabata K, Mizuguchi H (2010) Prevention of hepatic ischemia-reperfusion injury by pre-administration of catalase-expressing adenovirus vector. *J Control Rel*, **142**, 4331-4337.

Saeki R, **Kondoh M,** Uchida H, Yagi K (2010) Potency of Claudin-targeting as Antitumor Therapy. *Molecular and Cellular Pharmacology*, **2**, 47-51.

Kondoh M, Saeki R, Kakutani H, Hamakubo T, Watari A, and Yagi K (2010) Preparation of a claudin-4-targeted anti-tumor molecule. *FASEB J.*, **24**, 964.3.

Suzuki H, **Kondoh M,** Kakutani H, Hamakubo T, Watari A, and Yagi, K (2010) Development of a novel nasal vaccine using a claudin-4 binder. *FASEB J.*, **24**, 773.4.

近藤 昌夫 (2010) 生体バリアの分子基盤を利用した創薬研究 *薬剤学*, 70, 309-313.

Kakutani H, Takahashi A, **Kondoh M**, Saito Y, Yamaura T, Sakihama T, Hamakubo T, Yagi K (2011) A novel screening system for claudin binder using baculoviral display. *PLoS ONE*, 6, e16611.

Takahashi A, **Kondoh M**, Suzuki H, Kodaka M, Yagi K (2011) Claudin as a target for drug development. *Curr Med Chem*, 18, 1861-1865.

Yoshida T, **Kondoh M**, Yagi K (2011) Promising targets for anti-hepatitis C virus agents. *Curr Med Chem*, 18, 1239-1244.

Suzuki H, **Kondoh M,** Yoshida T, Takahashi A, Matsuhisa K, Kakamu Y, Kodaka M, Isoda K, Yagi K (in press) A toxicological evaluation of a claudin modulator, C-terminal fragment of Clostridium perfringens enterotoxin, in mice. *Pharmazie*.

Takahashi A, <u>Kondoh M</u>, Kodaka M, Yagi K（in press）Peptides as tight junction modulators. *Curr Pharm Design*.

Yoshida T, <u>Kondoh M,</u> Ojima M, Mizuguchi H, Yamagishi Y, Sakamoto N, Yagi K（in press）Adenovirus vector-mediated assay system for hepatitis C virus replication. *Nucleic Acid Res*.

Suzuki T, Sasaki T, Yano K, Sakurai F, Kawabata K, <u>Kondoh M,</u> Yagi K, Mizuguchi H（in press）Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome. *Virus Res*.

G-2 学会発表

渡利彰浩, <u>近藤昌夫</u>, 八木清仁：Claudin 発現の迅速かつ簡便なモニタリングシステムの開発 日本薬学会 第130年会 岡山 平成 22 年 3 月

渡利 彰浩、<u>近藤 昌夫</u>、八木 清仁；上皮細胞バリアに着目した食物アレルギーリスク評価 第 37 回日本トキシコロジー学会 平成 22 年 6 月 沖縄

渡利 彰浩、<u>近藤 昌夫</u>、八木 清仁；Claudin 発現モニタリングシステムを用いた Tight junction 調節物質の検索 第 131 回日本薬学会 平成 23 年 3 月 静岡

松久幸司、佐伯理恵、角谷秀樹、渡利彰浩、<u>近藤昌夫</u>、八木清仁；Claudin-4 を標的とした癌ターゲッティング法の開発 日本薬剤学会第 25 年会 平成 22 年 5 月 徳島

鈴木英彦、角谷秀樹、深坂昌弘、渡利彰浩、<u>近藤昌夫</u>、八木清仁；Claudin-4 binder を利用した粘膜ワクチンの開発 日本薬剤学会第 25 年会 平成 22 年 5 月 徳島

各務洋平、内田博司、花田雄志、高橋梓、山浦利

章、松久幸司、<u>近藤昌夫</u>、八木清仁；Claudin を利用したペプチド医薬品の非侵襲性投与技術の開発 日本薬剤学会第 25 年会 平成 22 年 5 月 徳島

鈴木英彦、佐伯理恵、角谷秀樹、渡利彰浩、<u>近藤昌夫</u>、八木清仁；Claudin binder を利用した癌治療法の開発 第 26 回日本 DDS 学会 平成 22 年 6 月 大阪

松久幸司、内田博司、花田雄志、高橋梓、各務洋平、<u>近藤昌夫</u>、八木清仁；Claudin-4 modulator を利用したペプチド医薬品の粘膜吸収促進法の開発 第 26 回日本 DDS 学会学術集会 平成 22 年 6 月 大阪

髙橋梓、斉藤郁美子、松久幸司、渡利彰浩、<u>近藤昌夫</u>、八木清仁；Clostridium perfringens enterotoxin を利用した claudin-1 binder の創製 第 26 回日本 DDS 学会 平成 22 年 6 月 大阪

髙橋梓、松久幸司、各務洋平、内田博司、花田雄志、<u>近藤昌夫</u>、八木清仁；Clostridium perfringens enterotoxin を利用した非侵襲性投与法の開発 第 57 回トキシンシンポジウム 平成 22 年 7 月 滋賀

髙橋梓、松久幸司、各務洋平、<u>近藤昌夫</u>、八木清仁；Claudin を標的とした非侵襲性投与技術の開発 第 60 回日本薬学会近畿支部総会・大会 平成 22 年 10 月 大阪

各務洋平、内田博司、花田雄志、高橋梓、<u>近藤昌夫</u>、八木清仁；高親和性 claudin binder の創製およびドラッグデリバリーシステムへの応用 BIA symposium 2010 平成 22 年 7 月 東京

各務洋平、高橋梓、松下恭平、松久幸司、<u>近藤昌夫</u>、八木清仁；新規 claudin modulator の創製およびドラッグデリバリーシステムへの応用 第 9 回次世代を担う若手ファーマ・バイオフォーラム 2010

平成 22 年 10 月 京都

松下恭平、高橋梓、斉藤郁美子、松久幸司、渡利彰浩、近藤昌夫、八木清仁；Claudin modulator を利用した非侵襲的投与技術の開発 第9回次世代を担う若手ファーマ・バイオフォーラム 2010 平成 22 年 10 月 京都

Yohei Kakamu, Hiroshi Uchida, Takeshi Hanada, Azusa Takahashi, Masuo Kondoh, Kiyohito Yagi, A claudin modulator as a mucosal absorption-enhancer of a peptide drug 日本薬物動態学会第 25 回年会 平成 22 年 10 月 東京

鈴木英彦、角谷秀樹、深坂昌弘、渡利彰浩、近藤昌夫、八木清仁；Claudin-4 binder を標的とした新規粘膜ワクチンの創製 日本ワクチン学会第 14 年会 平成 22 年 12 月 東京

松下恭平、高橋梓、斉藤郁美子、松久幸司、渡利彰浩、近藤昌夫、八木清仁；Claudin modulator を利用した非侵襲的投与技術の開発 第 83 回日本生化学会大会 平成 22 年 12 月 神戸

小高美樹、高橋梓、山浦利章、松久幸司、松下恭平、渡利彰浩、近藤昌夫、八木清仁；ファージ抗体ライブラリを用いた新規 claudin binder スクリーニングシステムの構築 日本薬学会第 131 年会 平成 23 年 3 月 静岡

各務洋平、松下恭平、高橋梓、松久幸司、斉藤郁美子、青山浩、宇野公之、近藤昌夫、八木清仁；新規 claudin binder C-CPEm19 の機能ドメイン解析 日本薬学会第 131 年会 平成 23 年 3 月 静岡

山根誠司、鈴木英彦、角谷秀樹、高橋梓、松久幸司、内田博司、渡利彰浩、近藤昌夫、八木 清仁；新規 claudin binder の創製と粘膜ワクチンへの応用 日本薬学会第 131 年会 平成 23 年 3 月 静岡

髙橋梓、近藤昌夫、八木清仁；Claudin binder を利用した創薬基盤研究 日本薬学会第 131 年会 平成 23 年 3 月 静岡

近藤昌夫、八木清仁；Claudin modulator を利用した粘膜吸収促進法の現状と課題；日本薬学会第 131 年会 平成 23 年 3 月 静岡

Azusa Takahashi, Masuo Kondoh, Hideki Kakutani, Toshiko Sakihama, Takao Hamakubo, Akihiro Watari, Kiyohito Yagi, A novel screening system for claudin binder using baculoviral display. Experimental Biology 2010, Apr 24-28, Anaheim, CA, USA.

Hidehiko Suzuki, Masuo Kondoh, Hideki Kakutani, Takao Hamakubo, Akihiro Watari, Kiyohito Yagi, Development of a novel nasal vaccine using a claudin-4 binder, Experimental Biology 2010, Apr, 2010,Anaheim, California, USA.

Masuo Kondoh, Rie Saeki, Hideki Kakutani, Yasuhiro Mochizuki, Takao Hamakubo, Akihiro Watari, Kiyohito Yagi, Preparation of a claudin-4-targeted anti-tumor molecule. Experimental Biology 2010, Apr 24-28, 2010, Anaheim, CA, USA.

Hiroshi Uchida, Masuo Kondoh, Takeshi Hanada, Azusa Takahashi, Takao Hamakubo, Kiyohito Yagi, A claudin-4 modulator enhances the mucosal absorption of peptide. Experimental Biology 2010, Apr 24-28, 2010, Anaheim, CA, USA.

Hidehiko Suzuki, Rie Saeki, Masuo Kondoh, Kiyohito Yagi, A novel strategy for cancer-targeting using claudin-4 binder. 37th annual meeting & exposition of the Controlled Release Society, July 10-14, 2010, Portland, OR, USA.

Hidehiko Suzuki, Hideki Kakutani, Akihiro Watari, **Masuo Kondoh**, Kiyohito Yagi, Development of a Mucosal Vaccine Using a Claudin-4 Binder. FIP Pharmaceutical Sciences World Congress 2010, Nov 14-18, 2010, Louisiana, USA.

Yohei Kakamu, Hiroshi Uchida, Takeshi Hanada, Azusa Takahashi, **Masuo Kondoh**, Kiyohito Yagi, Development of a non-invasive drug delivery system using a claudin modulator. FIP Pharmaceutical Sciences World Congress 2010, Nov 14-18, 2010, Louisiana, USA.

Hidehiko Suzuki, Hideki Kakutani, Takeshi Yoshida, **Masuo Kondoh**, Kiyohito Yagi, Development of mucosal vaccine using a claudin binder. 50th annual meeting of the American society for cell biology, Dec 11-15, Philadelphia, USA.

H. 知的財産権の出願・登録状況

H-1 特許取得
該当事項なし

H-2 実用新案登録
該当事項なし

H-3 その他
該当事項なし

## I. 研究協力者
吉田孟史

山岸善彰

松久幸司

各務洋平

Figure 1 Effect of C-CPEs on infection of Huh7 cells with HCVpv
After 2 h of incubation of anti-CD81 antibody (A) or C-CPEm19 (B) at the indicated concentration, Huh7 cells were treated with the mixture for 24 h. Then, the cells were lysed, and the luciferase activity was measured. Data are means ± SD (n=3).

24

WT-BV   CLA-BV   CLB-BV

Figure 2 Induction of anti-CL antibody in mice immunized with CL-BV.
WT-BV or CL-BV (0.5 mg/lane) were subjected to SDS-PAGE, followed by immunoblot analysis with the mouse serum.


Figure 3 Enrichment of phages with affinity to CL1-BV.
CL1-BV coated on immunotubes were incubated with the scFv phage library. The phages bound to CL1-BV were recovered (1st output phage). The CL1-BV-binding phages were subjected to two additional panning cycles, resulting in 2nd, 3rd output phage. The ratio of output phage to input phage titers was calculated

Figure 4 Monoclonal analysis of scFv phages.
CL1-BV-bound phage clones were isolated, and the interaction of the monoclonal phage with CL1-BV was examined by ELISA with HRP-anti-M13 Ab.


Figure 5 Interaction of scFv-phage clones with CL-B
Each phage clones were added onto BV-coated immunoplate, and BV-bound phages were detected by ELISA with HRP-anti-M13 mAb.

Table 1 Amino acid sequence of CL-BV-bound scFv clones

VL	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	(G4S)3
Clone A C D	DIQMTQSQKFMS TSVGDRVSVTC	xxxxxx xxxx	WYQQKPG QSPKALIY	xxxxxxx	GVPDRFTGSGSGTDF TLTISNVQSEDLAEYFC	xxxxxxx	FGAGTKLELKR	GGGGSGGGG SGGGGS
Clone B	DIVITQSHKFMST SVGDRVSITC	KASQDV GTAVA	WYQQKPG QSPKLLIY	xxxxxx	GVPDRFTGSGSGTDFT LTISNVQSEDLADYFC	xxxxxxxxxx	FGAGTKLEVKR	GGGGSGGGG SGGGGS

VH	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
Clone A C D	QVQLQQPGTELVKPG ASVKMSCKASGYTFS	xxxxx	WVKQRPG QGLEWIG	xxxxxxxxxx xxxxx	KATLTVDTASSTAYMQ LSRLTSEDSAVYYCAR	xxxxxxxxxx xxxxxxx	WGQGTTLQSSS
Clone B	DVQLVESGAELAKPG ASVKLSCKASGFTFT	xxxxx	WVKQRPG QGLEWIG	xxxxxxxx xxxxxxx	KATLTVDTSSNTAYMQ LSSLTSEDSAVYYCAR	xxxxxxxxxx xxxxxxx	WGQGTTLQSSS

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
	該当事項なし						

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Itoh A. Itoh A., **Isoda K.**, Kondoh M., Kawase M., Watari A., Kobayashi M.	Hepatoprotective effect of syringic acid and vanillic acid on CCl4-induced liver injury	*Biol. Pharm. Bull.,*	33	983-987	2010
Yagi K, Kawase M, Isoda K, Kondoh M	Development of novel culture system for regulation of hepatocyte function.	*Yakugaku Zasshi.*	130	537-543	2010
Nagano Yoshioka Y., Watanabe H., Morishige T., Yao X., Ikemizu S., Nagao C., Ahmad S., Mizuguchi K., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N. and Nakagawa S	Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.	Biomaterials	31	1935-1943	2010
Yamashita T., Utoguchi N., Suzuki R., Nagano K., Tsunoda S., Tsutsumi Y. and Maruyama K.	Development of anti-tumor blood vessel antibodies by phage display method	Yakugaku Zasshi	130	479-485	2010
Shibata H., Abe Y., Yoshioka Y., Nomura T., Sato M., Kayamuro H., Kawara T., Arita S., Furuya T., Nagano K., Yoshikawa T., Kamada H., Tsunoda S. and Tsutsumi Y	Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2	Cytokine	50	75-83	2010

28

Nomura T., Abe Y., Kamada H., Inoue M., Kawara T., Arita S., Furuya T., Minowa K., Yoshioka Y., Shibata H., Kayamuro H., Yamashita T., Nagano K., Yoshikawa T., Mukai Y., Nakagawa S., Tsunoda S. and Tsutsumi Y.	Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.	Pharmazie	65	93-96	2010
Nagano K., Imai S., Nakagawa S., Tsunoda S. and Tsutsumi Y.	From disease proteomics to biomarker development-establishment of antibody proteomics technology and exploration of cancer-related biomarkers	Yakugaku Zasshi	130	487-492	2010
Mukai Y., Nakamura T., Yoshikawa M., Yoshioka Y., Tsunoda S., Nakagawa S., Yamagata Y. and Tsutsumi Y.	Solution of the Structure of the TNF-TNFR2 Complex.	Science Signal.	3	ra83	2010
Morishige T., Yoshioka Y., Tanabe A., Yao X., Mizuguchi H., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N. and Nakagawa S.	Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models.	Int. Immunopharmacol.	10	26-33	2010
Morishige T., Yoshioka Y., Inakura H., Tanabe A., Yao X., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N. and Nakagawa S.	Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.	Biomaterials	31	3357-3363	2010
Morishige T., Yoshioka Y., Inakura H., Tanabe A., Yao X., Tsunoda S., Tsutsumi Y., Mukai Y., Okada N. and Nakagawa S.	Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor.	Biochem Biophys Res Commun.	393	888-893	2010

Authors	Title	Journal	Volume	Pages	Year
Kayamuro H., Abe Y., Yoshioka Y., Katayama K., Yoshida T., Yamashita K., Yoshikawa T., Kawai Y., Mayumi T., Hiroi T., Itoh N., Nagano K., Kamada H., Tsunoda S. and Tsutsumi Y.	TNF-alpha, mTNF-K90R, is a novel candidate adjuvant for a mucosal vaccine against HIV.	Pharmazie	65	254-256	2010
Suzuki H Kakutani H Kondoh M Watari A Yagi K	The safety of a mucosal vaccine using the C-terminal fragment of *Clostridium perfringens* enterotoxin	*Pharmazie*	10	766-769	2010
Itoh A Isoda K Kondoh M Kawase M Watari A Kobayashi M Tamesada M Yagi K	Hepatoprotective effect of syringic acid and vanillic acid on CCl_4-induced liver injury	*Biol Pharm Bull*	33	983-987	2010
Kakutani H Kondoh M Fukasaka M Suzuki H Hamakubo T Yagi K	Mucosal vaccination using claudin-4 targeting	*Biomaterials*	31	5463-5471	2010
Yagi K Kawase M Isoda K Kondoh M	Development of novel culture system for regulation of hepatocyte function	*YAKUGAKU ZASSHI,*	130	537-543	2010
Kakutani H Kondoh M Saeki R Fujii M Watanabe Y Mizuguchi H Yagi K	Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of *Clostridium perfringens* enterotoxin	*Eur J Pharm Biopharm*	75	213-217	2010
Uchida H Kondoh M Hanada T Takahashi A Hamakubo T Yagi K	A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide	*Biochem Pharmacol*	79	1437-1444	2010
Ushitora M Sakurai F Yamaguchi T Nakamura S Kondoh M Yagi K Kawabata K Mizuguchi H	Prevention of hepatic ischemia-reperfusion injury by pre-administration of catalase-expressing adenovirus vector	*J Control Rel*	142	4331-4337	2010

Saeki R Kondoh M Uchida H Yagi K	Potency of claudin-targeting as antitumor therapy	*Mol Cell Pharmacol*	2	47-51	2010
近藤昌夫	生体バリアの分子基盤を利用した創薬研究	*薬剤学*	70	309-313	2010
Saeki R Kondoh M Kakutani H Matsuhisa K Takahashi A Suzuki H Kakamu Y Watari A Yagi K	A claudin-targeting molecule as an inhibitor of tumor metastasis	*J Pharmacol Exp Ther*	334	576-582	2010
Kakutani H Takahashi A Kondoh M Saito Y Yamaura T Sakihama T Hamakubo T Yagi K	A novel screening system for claudin binder using baculoviral display	*PLoS ONE*	6	e16611	2011
Takahashi A Kondoh M Suzuki H Kodaka M Yagi K	Claudin as a target for drug development	*Curr Med Chem*	18	1861-1865	2011
Yoshida T Kondoh M Yagi K	Promising targets for anti-hepatitis C virus agents	*Curr Med Chem*	18	1239-1244	2011
Suzuki T Sasaki T, Yano K, Sakurai F Kawabata K Kondoh M Yagi K Mizuguchi H	Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome	*Virus Res*			accepted
Yoshida T Kondoh M Ojima M Mizuguchi H Yamagishi Y Sakamoto N Yagi K	Adenovirus vector-mediated assay system for hepatitis C virus replication	*Nucleic Acid Res*			accepted
Suzuki H Kondoh M Yoshida T Takahashi A Matsuhisa K Kakamu Y Kodaka M Isoda K Yagi K	A toxicological evaluation of a claudin modulator, C-terminal fragment of Clostridium perfringens enterotoxin, in mice	*Pharmazie*			accepted

Takahashi A Kondoh M Kodaka M Yagi K	Peptides as tight junction modulators	*Curr Pharm Design*			accepted

Hepatoprotective Effect of Syringic Acid and Vanillic Acid on CCl₄-Induced Liver Injury

Ayano Itoh,[a] Katsuhiro Isoda,[a] Masuo Kondoh,[a] Masaya Kawase,[a] Akihiro Watari,[a]
Masakazu Kobayashi,[b] Makoto Tamesada,[b] and Kiyohito Yagi*,[a]

[a] Graduate School of Pharmaceutical Sciences, Osaka University; 1–6 Yamada-oka, Suita, Osaka 565–0871, Japan: and
[b] Research and Development Center, Kobayashi Pharmaceutical Co., Ltd.; 1–30–3 Toyokawa, Ibaraki, Osaka 567–0057,
Japan.   Received December 22, 2009; accepted March 16, 2010; published online March 19, 2010

The mycelia of the edible mushroom *Lentinula edodes* can be cultured in solid medium containing lignin, and the hot-water extracts (L.E.M.) is commercially available as a nutritional supplement. During the cultivation, phenolic compounds, such as syringic acid and vanillic acid, were produced by lignin-degrading peroxidase secreted from *L. edodes* mycelia. Since these compounds have radical scavenging activity, we examined their protective effect on oxidative stress in mice with CCl₄-induced liver injury. We examined the hepatoprotective effect of syringic acid and vanillic acid on CCl₄-induced chronic liver injury in mice. The injection of CCl₄ into the peritoneal cavity caused an increase in the serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. The intravenous administration of syringic acid and vanillic acid significantly decreased the levels of the transaminases. Four weeks of CCl₄ treatment caused a sufficiently excessive deposition of collagen fibrils. An examination of Azan-stained liver sections revealed that syringic acid and vanillic acid obviously suppressed collagen accumulation and significantly decreased the hepatic hydroxyproline content, which is the quantitative marker of fibrosis. Both of these compounds inhibited the activation of cultured hepatic stellate cells, which play a central role in liver fibrogenesis, and maintained hepatocyte viability. These data suggest that the administration of syringic acid and vanillic acid could suppress hepatic fibrosis in chronic liver injury.

Key words   hepatoprotection; *Lentinula edodes*; syringic acid; vanillic acid; polyphenol

The edible mushroom *Lentinula edodes* (shiitake) contains bioactive compounds that have immune-modulating, antitumor, antibacterial, antiviral, and antiparasitic effects.[1—4] The mycelia of *L. edodes* can be cultured in solid medium, and the hot-water extract (L.E.M.) is commercially available as a nutritional supplement. The main components of L.E.M. are sugars, proteins, and polyphenolic compounds. Polyphenols have protective effects against cancers, cardiovascular disease, and neurodegenerative disorders.[5—7] Among polyphenols, syringic acid and vanillic acid are enriched in the solid medium of cultured *L. edodes* mycelia.[8] *L. edodes* grown in lignocellulose secretes lignin-degrading peroxidase into the culture medium.[9] The mycelia-derived enzymes degrade the lignin to produce phenolic compounds, particularly syringic acid and vanillic acid. In our previous study, we demonstrated that these phenolic compounds had a hepatoprotective effect on concanavalin A (ConA)-induced liver injury in mice.[8] We intraperitoneally injected syringic acid or vanillic acid into mice shortly before a ConA injection into the tail vein, which greatly increased the levels of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT). In addition, the inflammatory cytokines tumor necrosis factor (TNF)-α, interferon-γ (IFN-γ), and interleukin (IL)-6 in the serum increased rapidly, within 3 h of the ConA administration. The administration of syringic acid or vanillic acid significantly decreased the transaminase and inflammatory cytokine levels and suppressed the disorganization of the hepatic sinusoids. Since ConA-induced liver injury is a mouse model of immune-mediated liver injury that resembles viral and autoimmune hepatitis in humans, the phenolics appeared to have immunomodulating activity.

Polyphenols act as antioxidants by scavenging reactive oxygen species (ROS), which produce oxidative stress and can adversely affect many cellular processes. In the present study, we examined the possible hepatoprotective effects of two phenolic compounds, syringic acid and vanillic acid, on oxidative stress in chronic CCl₄-induced liver injury in mice. We found that both phenolic compounds could suppress oxidative damage, especially liver fibrosis caused by repeated administration of CCl₄.

MATERIALS AND METHODS

Reagents   Syringic acid, vanillic acid, and CCl₄ were purchased from WAKO Pure Chemicals, Co., Ltd. (Osaka, Japan). The chemical structures of syringic acid and vanillic acid were shown in Fig. 1. L.E.M. was obtained from Kobayashi Pharmaceutical Co., Ltd. (Osaka, Japan). CCl₄ was dissolved in olive oil, and L.E.M., syringic acid, and vanillic acid were dissolved in phosphate buffered saline (PBS) for administration into mice. L.E.M., syringic acid, and vanillic acid were dissolved in culture medium for hepatocytes or hepatic stellate cells for *in vitro* experiments.

Animals   BALB/c mice and Sprague-Dawley rats were purchased from SLC (Shizuoka, Japan). The animals were housed in an air-conditioned room at 22 °C before the experiment. The animal experiments were conducted according to the ethical guidelines of Osaka University Graduate School


Fig. 1.   Chemical Structures of Syringic Acid and Vanillic Acid

of Pharmaceutical Sciences. The experimental protocol was submitted to the Committee on the Guidelines for Animal Experiments in Graduate School of Pharmaceutical Sciences, and the experiments were conducted after gaining the approval. Mice in the chronic liver injury model received intraperitoneal injections of CCl_4 (0.5 ml/kg body weight) and intravenously administered L.E.M., syringic acid, or vanillic acid (10 mg/kg body weight) twice a week for 4 weeks. Twenty-four hours after the L.E.M., syringic acid, or vanillic acid injection, the mice were anesthetized. Then, blood samples were collected to determine the transaminase activity, and the livers were excised for Azan staining and determination of hydroxyproline and malondialdehyde.

Assays Serum AST and ALT levels were measured by using an assay kit (Transaminase C-II, WAKO, Osaka, Japan).

Histological Analysis Liver specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were cut from the tissue blocks and mounted on slides. Azan staining was then performed to evaluate the extent of liver fibrosis.

Measurement of Hydroxyproline Content Hepatic hydroxyproline content was measured by using Kivirikko's method[10] with some modifications. Briefly, liver tissue (50 mg) was hydrolyzed with 6 mol/l HCl at 110 °C for 24 h in a glass test tube. After centrifugation at 3000 rpm for 10 min, 2 ml of the supernatant was neutralized with 8 N KOH. Two grams of KCl and 1 ml of 0.5 mol/l borate buffer were then added to the neutralized supernatant, followed by a 15-min incubation at room temperature and then a 15-min incubation at 0 °C. Freshly prepared chloramine-T solution was then added, and the sample was incubated at 0 °C for 1 h, followed by the addition of 2 ml of 3.6 mol/l sodium thiosulfate. The samples were incubated at 120 °C for 30 min. Then, 3 ml of toluene was added, and the samples were incubated for 20 min at room temperature. After centrifugation at 2000 rpm for 5 min, 2 ml of the supernatant was added to 0.8 ml buffer containing Ehrlich's reagent and incubated for 30 min at room temperature. The samples were then transferred to a plastic tube, and the absorbance was measured at 560 nm. The hydroxyproline content was expressed as micrograms of hydroxyproline per gram of liver.

Measurement of Malondialdehyde Lyophilized liver tissue (25 mg) was boiled for 30 min in a solution containing 250 ml of 1.15% KCl, 150 ml of 1% H_3PO_4, and 500 ml of 0.67% thiobarbituric acid. Two milliliters of n-butanol was added to the ice-chilled sample, and then the sample was stirred for 30 min. After centrifugation at $3000 \times g$ for 10 min, the upper n-butanol phase was collected, and the amount of malondialdehyde was colorimetrically determined at 535 and 520 nm.

Isolation and Culture of Hepatic Stellate Cells Hepatic stellate cells (HSCs) were isolated from 10-week-old male Sprague-Dawley rats by digesting the liver with Pronase-E (Merck Darmstadt, Germany) and collagenase type I (WAKO Pure Chemicals Co., Osaka, Japan) as previously described.[11] Isolated HSCs were seeded at a density of 2×10^5 cells/cm^2 onto 24-well polystyrene culture plates (Asahi Techno Glass, Funabashi, Chiba, Japan) to observe the morphology and analyze fibrosis-related gene expression. Cells were cultured in Dulbecco's modified Eagle's medium

(Sigma, St. Louis, MO, U.S.A.) supplemented with 10% fetal bovine serum.

Isolation and Culture of Hepatocytes Hepatocytes were isolated from male BALB/c mice by perfusing the liver with collagenase, according to the method of Seglen.[12] Cells were seeded at a density of 1×10^5 cells/cm^2 into multi-well culture plates pre-coated with collagen type I (Asahi Techno Glass, Funabashi, Chiba, Japan). The basal medium consisted of 50 U/ml penicillin G, 50 μg/ml streptomycin (ICN Biochemicals, Inc., Costa Mesa, CA, U.S.A.), 1 μM insulin, 1 μM dexamethasone (WAKO Pure Chemicals Co., Osaka, Japan), and 10% fetal bovine serum in William's medium E (MP Biomedicals, Inc., Kayserberg, France). Six hours after the cells were seeded, the basal medium was replaced with medium containing L.E.M., syringic acid, or vanillic acid at a final concentration of 1.0 mg/ml without insulin and dexamethasone. Cells were then cultured for 24—48 h, and viable cells were counted after trypan blue staining.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) The HSCs were cultured for 7 d and the total RNA was extracted using High Pure RNA Isolation Kit (Roche, Mannheim, Germany). The gene expression of collagen 1 α(1) was analyzed using the following primers: forward 5'-TGCCGTGACCTCAAGATGTG-3' and reverse 5'-CAC-AAGCGTGCTGTAGGTGA-3'. The gene expression of a smooth muscle actin (α-SMA) was analyzed using the following primers: forward 5'-CCGAGATCTCACCGAC-TACC-3' and reverse 5'-TCCAGAGCGACATAGCACAG-3'. The gene expression of β-actin was analyzed using the following primers: forward 5'-CCCAGAGCAAGAGAGGC-ATC-3' and reverse 5'-CTCAGGAGGAGCAATGATCT-3'.

The RT-PCR was examined using RNA PDR Kit (TaKaRa, Kyoto, Japan).

Statistical Analysis The data were analyzed for statistical significance by using Student's t-test and Dunnett's test.

RESULTS

Effect on CCl_4-Induced Chronic Liver Injury We examined the hepatoprotective effect of syringic acid and vanillic acid on CCl_4-induced chronic liver injury in mice. As shown in Fig. 2, after 4 weeks of CCl_4 treatment, the activities of blood AST and ALT increased 30-fold and 127-fold, respectively, compared with controls. The intravenous administration of syringic acid or vanillic acid significantly decreased the activities of AST and ALT. These results suggest that syringic acid and vanillic acid suppress the hepatic inflammation caused by repeated CCl_4 treatments. We also examined the effect of syringic acid and vanillic acid on liver fibrogenesis. Figure 3 shows typical Azan staining results, in which fibrous materials are stained blue. In the controls (Fig. 3A), hardly any blue staining was observed in the pericentral area. In contrast, the livers injured by chronic CCl_4 treatment displayed a considerable accumulation of fibrous materials (Fig. 3B). CCl_4 treatment for 4 weeks caused an excessive deposition of collagen fibrils that was sufficient for the evaluation of the antifibrogenic effect of syringic acid and vanillic acid. Based on the results of Azan staining, the syringic acid and vanillic acid treatments obviously suppressed collagen accumulation (Figs. 3D, E). To quantitatively evaluate the effect of syringic acid and vanillic acid on fibrogenesis, we

Fig. 2. Effect of Syringic Acid and Vanillic Acid on CCl₄-Induced Chronic Hepatic Injury

Mice received an intraperitoneal injection of CCl₄ and an intravenous injection of L.E.M., syringic acid, or vanillic acid twice a week for 4 weeks. The serum levels of AST (solid column) and ALT (open column) were determined. The values are mean±S.D ($n=4$). The data were analyzed by Student's t-test ($\#p<0.05$, as compared to uninjured control mice) and Dunnett's method ($*p<0.05$, as compared to CCl₄-injured control mice).


Fig. 4. Effect of Syringic Acid and Vanillic Acid on the Hydroxyproline Content of the Liver

The hydroxyproline content of the liver was measured after 4 weeks of treatments. The values are mean±S.D. ($n=4$). The data were analyzed by Student's t-test ($\#\#p<0.01$, as compared to uninjured control mice) and Dunnett's method ($*p<0.05$, as compared to CCl₄-injured control mice).


Fig. 5. Effect of Syringic Acid and Vanillic Acid on the Suppression of Oxidative Stress

The malondialdehyde content of the liver was determined after 4 weeks of experiments. The values are mean±S.D. ($n=4$). The data were analyzed by Student's t-test ($\#\#p<0.01$, as compared to uninjured control mice) and Dunnett's method ($*p<0.05$, as compared to CCl₄-injured control mice).

Fig. 3. Azan Staining of Liver Sections

Livers were excised from normal mice (A), CCl₄-injured control mice (B), L.E.M.-treated mice (C), syringic acid-treated mice (D), and vanillic acid-treated mice (E). Original magnification ×400.

measured the hepatic hydroxyproline content, which parallels the extent of fibrosis. After 4 weeks of CCl₄ treatment, the hepatic hydroxyproline content increased 4.6-fold as compared with the controls (Fig. 4). The intravenous administration of syringic acid or vanillic acid significantly decreased the hepatic hydroxyproline content. These data suggest that syringic acid and vanillic acid can suppress hepatic fibrosis in chronic liver injury. Next, we measured the amount of malondialdehyde in the liver samples as a marker of oxidative stress. The malondialdehyde content was drastically increased after 4 weeks of CCl₄ treatment, but the intravenous administration of syringic acid or vanillic acid significantly

decreased the malondialdehyde content to an almost normal level (Fig. 5). The protective effects of syringic acid and vanillic acid were almost comparable to that of L.E.M. (Figs. 2—5).

***In Vitro* Effect on HSC Activation and Hepatocyte Viability** We examined the direct effect of syringic acid and vanillic acid on the activation of HSCs, which play a central role in liver fibrogenesis, using the monolayer culture. HSCs are activated during the monolayer culture to transform into proliferating myofibroblast-like cells. As shown in Fig. 6A, HSCs were activated after 7 d of culture to be fibroblastic cell-type. The addition of syringic acid or vanillic acid dose-dependently suppressed the activation (Fig. 6B). HSCs maintained their quiescent state by the addition of more than 0.5 mg/ml of the respective compound. Next, the effect of syringic acid and vanillic acid on gene expression of Type I collagen and α-SMA, which are markers of activated HSCs, was examined. HSCs were cultured for 7 d in the presence or absence of syringic acid or vanillic acid, and the gene expression was analysed by RT-PCR. As shown in Fig. 7, syringic acid and vanillic acid remarkably suppressed the expression of collagen and α-SMA genes, indicating that the phenolic compounds directly act on HSCs and suppress the activation

A

Day 0   Day 7

Control

B

Syringic acid

Vanillic acid

(mg/ml)   0.1   0.5   1.0

Fig. 6. Phase-Contrast Micrographs of Cultured HSCs

Freshly isolated HSCs were cultured for 7 d in the absence (A) and presence (B) of syringic acid or vanillic acid at the indicated concentration. Original magnification ×200.

|	Syringic acid			Vanillic acid		
(mg/ml)	0	0.1	0.5	1.0	0.1	0.5	1.0

Collagen 1α (I)

α-SMA

β-actin

Fig. 7. RT-PCR Analysis of Gene Expression Relating to HSC Activation

Bottom figure shows the relative expression of collagen 1 α(I) (closed bar) and α-SMA (open bar) compared with the non-addition control.

Fig. 8. Effect of Syringic Acid and Vanillic Acid on Viability of Cultured Hepatocytes

Freshly isolated hepatocytes were cultured for 24 h in the absence or presence of 1.0 mg/ml syringic acid or vanillic acid. Viability was measured by trypan blue exclusion test. The data were analyzed by Dunnett's method (*$p<0.05$, as compared to control).

to maintain the quiescent state. We then examined the effect of the compounds on liver parenchymal hepatocytes using the primary culture (Fig. 8). Hepatocytes were isolated and cultured in the presence or absence of syringic acid or vanillic acid. After 24 h of culture, viable cells were counted using trypan blue exclusion test. The addition of syringic acid or vanillic acid significantly maintained viability of cultured hepatocytes. These results suggested that syringic acid or vanillic acid might suppress liver fibrogenesis and inflammation by inhibiting HSC activation and protecting hepatocytes, respectively in chronically liver injured mice.

DISCUSSION

The physiological functions of plant-derived phenolic compounds have been extensively reported.[7,13,14] Syringic acid and vanillic acid possess antimicrobial, anti-cancer, and anti-DNA oxidation properties.[15—17] We recently found that syringic acid and vanillic acid could act as immunomodulators in mice with ConA-induced liver injury.[8] In the present study, we show that syringic acid and vanillic acid have protective effects in mice with CCl$_4$-induced liver injury. Both phenolic compounds dramatically suppressed liver fibrogenesis in the chronic CCl$_4$-treatment model. When these phenolics are orally administered to hamsters, they are adsorbed and appear in the blood within 40 min.[18] Although these compounds are intravenously administered in the present study, oral administration could also elicit the hepatoprotective effect. The syringic acid and vanillic acid contents in L.E.M. are 450 and 378 μg/g, respectively. Thus, the contents are relatively small, but these compounds are commercially available at low prices. Therefore, syringic acid and vanillic acid might be promising oral agents for the prevention of liver disease.

We evaluated the hepatoprotective effect of phenolic compounds in mice with CCl$_4$-induced liver injury. After intravenous administration, CCl$_4$ is introduced into the liver, where it is toxic to hepatocytes. Cytochrome P-450 in the endoplasmic reticulum of hepatocytes catalyzes the dehalogenation to produce an unstable complex trichloromethyl radical,[19] resulting in the extensive necrosis of hepatocytes that leads to liver inflammation. In the present study, the transaminase level in the serum was drastically increased by CCl$_4$ treatment. Generation of ROS degrade polyunsaturated lipids to form malondialdehyde, which is a marker of oxidative stress. The chronic CCl$_4$ treatment significantly increased the malondialdehyde content of the liver. Syringic acid and vanillic acid clearly suppressed the transaminase and malondialdehyde levels in CCl$_4$-treated mice. Since both of these compounds have 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity,[8] the suppression of ROS generation appears to be responsible for the hepatoprotective effect. Moreover, the CCl$_4$-induced liver fibrogenesis was suppressed by the administration of syringic acid and vanillic acid. The activation of HSCs is responsible for the development of liver fibrosis.[20,21] During liver injury with persistent inflammation, HSCs are activated to differentiate into proliferating myofibroblast-like cells and overproduce extracellular matrix, leading to fibrogenesis. Since HSCs are activated spontaneously during cell culture,[22] we examined the effect of syringic acid and vanillic acid on the activation of primary cell cultures of rat HSCs. Both of these compounds clearly inhibited the change from spherical to spindle shape and the expression of α-smooth muscle actin and collagen Type Iα genes, which are the markers of HSC activation. We also

examined the effect of syringic acid and vanillic acid on the maintenance of hepatocyte viability *in vitro*. Both of these compounds significantly maintained the viability of primary cell cultures of hepatocytes. Thus, syringic acid and vanillic acid could directly exert a physiological effect on hepatocytes and HSCs. Both phenolic compounds might affect CCl_4 metabolism to inhibit the generation of cytotoxic trichloromethyl radical in the liver. However, the direct effects of syringic acid and vanillic acid on HSCs and hepatocytes were shown in this study, and the protective effect was also shown in ConA-induced liver injured mice in our previous study.[8] Moreover, these phenolic compounds have strong radical scavenging activity. These results suggest that during the repeated treatment of CCl_4, these compounds could protect hepatocytes and HSCs from CCl_4-induced oxidative stress to suppress liver inflammation and fibrogenesis.

The hot-water extracts from cultured mycelia of *L. edodes* have versatile physiological effects and might contain promising seed compounds for pharmaceutical development. We have shown that syringic acid and vanillic acid have anti-oxidative and immunomodulating activities. In addition to these phenolics, L.E.M. could contain novel compounds with pharmaceutical potential. We are currently trying to isolate bioactive components from L.E.M.

REFERENCES

1) Wasser S. P., Weis A. L., *Crit. Rev. Immunol.*, **19**, 65—96 (1999).
2) Suzuki H., Okubo A., Yamazaki S., Suzuki K., Mitsuya H., Toda S., *Biochem. Biophys. Res. Commun.*, **160**, 367—373 (1989).
3) Yamamoto Y., Shirono H., Kono K., Ohashi Y., *Biosci. Biotechnol. Biochem.*, **61**, 1909—1912 (1997).
4) Yamada T., Oinuma T., Niihashi M., Mitsumata M., Fujioka T.,
Hasegawa K., Nagaoka H., Itakura H., *J. Atheroscler. Thromb.*, **9**, 149—156 (2002).
5) Aggarwal B. B., Kumar A., Bharti A. C., *Anticancer Res.*, **23**, 363—398 (2003).
6) Aviram M., Dornfeld L., Kaplan M., Coleman R., Gaitini D., Nitecki S., Hofman A., Rosenblat M., Volkova N., Presser D., Attias J., Hayek T., Fuhrman B., *Drugs Exp. Clin. Res.*, **28**, 49—62 (2002).
7) Levites Y., Weinreb O., Maor G., Youdim M. B., Mandel S., *J. Neurochem.*, **78**, 1073—1082 (2001).
8) Itoh A., Isoda K., Kondoh M., Kawase M., Kobayashi M., Tamesada M., Yagi K., *Biol. Pharm. Bull.*, **32**, 1215—1219 (2009).
9) Forrester I. T., Grabski A. C., Mishra C., Kelley B. D., Strickland W. N., Leatham G. F., Burgess R. R., *Appl. Microbiol. Biotechnol.*, **33**, 359—365 (1990).
10) Kivirikko K. I., Laitinen O., Prockop D. J., *Anal. Biochem.*, **19**, 249—255 (1967).
11) Kawada N., Tran-Thi T. A., Klein H., Decker K., *Eur. J. Biochem.*, **213**, 815—823 (1993).
12) Seglen P. O., *Methods Cell Biol.*, **13**, 29—83 (1976).
13) Gao X., Xu Y. X., Janakiraman N., Chapman R. A., Gautam S. C., *Biochem. Pharmacol.*, **62**, 1299—1308 (2001).
14) Aggarwal S., Ichikawa H., Takada Y., Sandur S. K., Shishodia S., Aggarwal B. B., *Mol. Pharmacol.*, **69**, 195—206 (2006).
15) Aziz N. H., Farag S. E., Mousa L. A., Abo Zaid M. A., *Microbios*, **93**, 43—54 (1998).
16) Guimaraes C. M., Giao M. S., Martinez S. S., Pintado A. I., Pintado M. E., Bento L. S., Malcata F. X., *J. Food Sci.*, **72**, C039–C043 (2007).
17) Kampa M., Alexaki V. I., Notas G., Nifli A. P., Nistikaki A., Hatzoglou A., Bakogeorgou E., Kouimtzoglou E., Blekas G., Boskou D., Gravanis A., Castanas E., *Breast Cancer Res.*, **6**, R63–R74 (2004).
18) Chen C. Y., Milbury P. E., Kwak H. K., Collins F. W., Samuel P., Blumberg J. B., *J. Nutr.*, **134**, 1459—1466 (2004).
19) Castillo T., Koop D. R., Kamimura S., Triadafilopoulos G., Tsukamoto H., *Hepatology*, **16**, 992—996 (1992).
20) Albanis E., Friedman S. L., *Clin. Liver Dis.*, **10**, 821—833 (2006).
21) Friedman S. L., *Toxicology*, **254**, 120—129 (2008).
22) Sato M., Suzuki S., Senoo H., *Cell Struct. Funct.*, **28**, 105—112 (2003).